Header Logo

Connection

Christopher Goetz to Hallucinations

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Hallucinations.
Christopher Goetz
Connection Strength
7.399
Hallucinations
  1. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.459
  2. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.442
  3. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.385
  4. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.379
  5. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.366
  6. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.346
  7. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.344
  8. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.332
  9. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.315
  10. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.310
  11. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.270
  12. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.268
  13. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.264
  14. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.245
  15. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.220
  16. Understanding visual hallucinations: A new synthesis. Neurosci Biobehav Rev. 2023 07; 150:105208.
    View in: PubMed
    Score: 0.218
  17. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.198
  18. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
    View in: PubMed
    Score: 0.187
  19. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
    View in: PubMed
    Score: 0.182
  20. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):287-9.
    View in: PubMed
    Score: 0.181
  21. [Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison]. Fortschr Neurol Psychiatr. 2000 Mar; 68(3):129-36.
    View in: PubMed
    Score: 0.175
  22. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol. 1999; 80:419-23.
    View in: PubMed
    Score: 0.161
  23. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998 Sep; 51(3):811-4.
    View in: PubMed
    Score: 0.158
  24. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998 Feb; 50(2):515-7.
    View in: PubMed
    Score: 0.152
  25. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology. 1995 Apr; 45(4):669-71.
    View in: PubMed
    Score: 0.124
  26. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.117
  27. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.076
  28. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 09; 66(9):1427-9.
    View in: PubMed
    Score: 0.067
  29. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.066
  30. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.062
  31. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004 Oct 26; 63(8):1409-16.
    View in: PubMed
    Score: 0.060
  32. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.059
  33. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry. 1982 Apr; 139(4):494-7.
    View in: PubMed
    Score: 0.051
  34. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.040
  35. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
    View in: PubMed
    Score: 0.039
  36. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology. 1993 Nov; 43(11):2227-9.
    View in: PubMed
    Score: 0.028
  37. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50.
    View in: PubMed
    Score: 0.020
  38. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May; 35(5):749-51.
    View in: PubMed
    Score: 0.016
  39. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.014
  40. Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology. 1981 Apr; 31(4):473-6.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.